PeopleBio Inc
PeopleBio, Inc., a biotech company, engages in developing diagnostics for protein misfolding diseases worldwide. Its Multimer Detection System technology uses capturing antibodies and epitope-overlapping detection antibodies for the detection of oligomers or multimers from monomers in protein-misfolding diseases. The company has strategic collaborations with Seoul National University Bundang Hosp… Read more
PeopleBio Inc (304840) - Total Liabilities
Latest total liabilities as of September 2025: ₩18.01 Billion KRW
Based on the latest financial reports, PeopleBio Inc (304840) has total liabilities worth ₩18.01 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PeopleBio Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how PeopleBio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PeopleBio Inc Competitors by Total Liabilities
The table below lists competitors of PeopleBio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Motio Ltd
AU:MXO
|
Australia | AU$1.67 Million |
|
Sego Resources Inc
V:SGZ
|
Canada | CA$470.19K |
|
Temas Resources Corp
OTCQB:TMASF
|
USA | $1.85 Million |
|
Italtile Ltd
JSE:ITE
|
South Africa | ZAC1.97 Billion |
|
VIQ Solutions Inc.
PINK:VQSSF
|
USA | $29.15 Million |
|
Saville Resources Inc
V:SRE
|
Canada | CA$483.15K |
|
Alset AI Ventures Inc.
PINK:GPUSF
|
USA | $780.13K |
Liability Composition Analysis (2017–2024)
This chart breaks down PeopleBio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PeopleBio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PeopleBio Inc (2017–2024)
The table below shows the annual total liabilities of PeopleBio Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩18.68 Billion | +122.16% |
| 2023-12-31 | ₩8.41 Billion | -78.01% |
| 2022-12-31 | ₩38.24 Billion | +11.05% |
| 2021-12-31 | ₩34.43 Billion | +1784.66% |
| 2020-12-31 | ₩1.83 Billion | +10.39% |
| 2019-12-31 | ₩1.66 Billion | +49.45% |
| 2018-12-31 | ₩1.11 Billion | +65.05% |
| 2017-12-31 | ₩670.98 Million | -- |